🇪🇸 100% SPAIN STOCK·FAST 24-72H DISPATCH

iberialabs
COMPOUND · TES-041526102% FILL
tesamorelin 10 mg
Growth
EXP: 04/2028

tesamorelin

Stimulates growth hormone secretion while reducing enzymatic susceptibility, resulting in a drastic and selective reduction of visceral and abdominal fat.

LOT:TES-041526
CALCULATOR↗LAB REPORT (COA)↗
OUT OF STOCK0 VIALS AVAILABLE IN STOCK
100% EU Delivery Guarantee— free reshipment if lost
24h EU dispatch from Spain · Zero customs risk
HPLC certified purity >99% on every batch
FOR LABORATORY USE ONLY — NOT FOR HUMAN CONSUMPTION. SHIPS FROM THE EU WITHIN 24 H, EU DELIVERY 3-7 DAYS, SPAIN 1-3 DAYS.

what the literature shows.

A condensed monograph drawn from preclinical and clinical literature, cited mechanisms, specifications and the research case for tesamorelin.

READ FULL ARTICLE →

Tesamorelin: GH Axis Stimulation and Selective Visceral Adipose Reduction

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog designed to stimulate the endogenous release of growth hormone while selectively targeting visceral fat.

Structural Parameters of Tesamorelin

PropertyValue and SpecificationReferences
CAS Number218949-48-5 (free base)
Molecular FormulaC221H366N72O67S (free base)
Molecular Weight5135.86 g/mol (free base)
Chemical Structure44-amino acid peptide with an N-terminal modification
Key Modifications3-hexenoyl group attached to the N-terminal Tyr1 residue

Origin, History, and Research Stage

Tesamorelin was developed by the Canadian biopharmaceutical firm Theratechnologies Inc. to address metabolic changes in patients with HIV-associated lipodystrophy. The drug received formal approval from the US FDA in November 2010 under the brand name Egrifta. It remains the only approved GHRH analog indicated specifically for the reduction of excess visceral abdominal fat in this patient population, and is actively studied for wider metabolic applications.

Mechanism of Action and Pharmacokinetics

Tesamorelin binds to and activates growth hormone-releasing hormone receptors (GHRHR) in the pituitary gland. It possesses the same 44-amino acid sequence as human GHRH, but the addition of a hydrophobic 3-hexenoyl group at the N-terminus shields the molecule from dipeptidyl peptidase-4 (DPP-4) degradation, increasing its systemic stability. Activation of GHRHR stimulates the synthesis and pulsatile release of endogenous growth hormone (GH). Elevated GH levels trigger the hepatic synthesis of insulin-like growth factor 1 (IGF-1). This elevated GH/IGF-1 axis drives lipolysis and reduces the size of visceral adipocytes.

Scientific and Clinical Effects

Clinical trials have established that daily subcutaneous administration of Tesamorelin reduces visceral adipose tissue (VAT) by an average of 15% to 18% over 26 weeks, without reducing beneficial subcutaneous fat. Furthermore, it has been shown to improve dyslipidemia by lowering triglycerides and non-HDL cholesterol, although patients require monitoring for potential changes in glucose tolerance.

Verified Reviews.

0 / 5.0
★★★★★
Based on 0 reviews
No reviews yet. Be the first to review this product.
/ FREQUENTLY ASKED QUESTIONS & PROTOCOLS

Frequently asked questions about tesamorelin.

Technical reconstitution protocols, HPLC purity verification, storage conditions, and express European delivery details.

tesamorelin is brought into solution using the diluent specified on its technical datasheet: sterile bacteriostatic water or 0.9% NaCl. Insert the syringe and direct the stream gently against the inner vial wall. Swirl smoothly with circular motions rather than shaking vigorously, as mechanical agitation can shear delicate peptide chains. Once reconstituted, it remains stable refrigerated at 2–8 °C for up to 28 days.

At Iberia Labs, every batch of tesamorelin is verified by High-Performance Liquid Chromatography (HPLC) at ≥ 99.734% purity, with bacterial endotoxin levels strictly under 0.5 EU/mg and identity confirmed by Mass Spectrometry (MS). Each batch is backed by its lot-specific Certificate of Analysis (current lot: TES-041526).

Lyophilized tesamorelin in vacuum-sealed vials should be stored at -20 °C, protected from light and moisture, with an unopened shelf life of 24 to 36 months. The sealed powder readily tolerates ambient temperature during transit without loss of potency. Upon receipt, transfer immediately to cold storage (-20 °C unopened, or 2–8 °C once reconstituted).

tesamorelin is available directly from Iberia Labs (iberialabs.eu), dispatched from warehouses within the European Union and Spain. Because shipments originate within the EU single market, orders are completely free from customs clearance delays. Orders dispatch within 24 hours, with 24–72 hour delivery in Spain and 2–5 business days across Europe.

Yes, tesamorelin may be legally purchased in Spain and throughout the European Union strictly for laboratory research, chemical analysis, and in-vitro or preclinical investigation (RUO). Iberia Labs supplies analytical-grade reagents exclusively to the scientific and research community. It is not an approved medicine and is not intended for human or animal consumption, nor for clinical diagnostics.

tesamorelin is available in individual vials (10 mg) starting at €64.95. Every order includes its verified lot-specific Certificate of Analysis at no extra cost. Prices are quoted in EUR and express shipping options are transparently calculated at checkout.

All confirmed orders of tesamorelin are dispatched within 24 business hours from our EU fulfillment facilities. Delivery across mainland Spain takes 24–72 hours via express courier. International European destinations arrive within 2–4 business days with secure and discreet packaging.

Yes. Every vial of tesamorelin is accompanied by an authentic Certificate of Analysis (CoA) for the current batch (TES-041526). The report documents HPLC purity chromatograms, mass spectrometry identity validation, and endotoxin assays. You can view and download the full laboratory report directly in our Lab Report (CoA) section.